Back to Library
Tissue RepairRecovery

KPV (Alpha-MSH Fragment)

Tripeptide for targeted inflammation control (Gut/Skin)

Overview

KPV (Lysine-Proline-Valine) is a naturally occurring C-terminal fragment of alpha-Melanocyte Stimulating Hormone (alpha-MSH). It is a potent anti-inflammatory peptide that inhibits the NF-kappaB pathway. Unlike steroids, it reduces inflammation without broadly suppressing the immune system. It is specifically studied for Inflammatory Bowel Disease (IBD) due to its unique ability to target inflamed tissues via the PepT1 transporter.

Chemical Information

IUPAC Name
Lysyl-Prolyl-Valine
Sequence
Lys-Pro-Val
Molecular Mass
342.4 Da
Formula
C16H30N4O4
KPV (Alpha-MSH Fragment) Chemical Structure

Mechanism of Action

Functions as a specialized anti-inflammatory tripeptide that acts as the C-terminal active fragment of α-Melanocyte Stimulating Hormone (α-MSH). Its primary mechanism is the inhibition of the NF-κB pathway, a master regulator of inflammation. Uniquely, KPV utilizes the PepT1 transporter (Solute Carrier Family 15 Member 1) to enter cells. This transporter is significantly upregulated in inflamed tissues (like the colon during colitis), allowing KPV to 'target' inflammation sites specifically rather than acting systemically. Once inside, it enters the nucleus to block NF-κB interactions, reducing the secretion of pro-inflammatory cytokines (TNF-α, IL-6) while preserving the body's antimicrobial defense.

Potential Research Fields

Inflammatory Bowel Disease (IBD)PsoriasisWound HealingCorneal RegenerationAutoimmunity

Recent Research

Recent research (2024–2025) highlights KPV as a promising alternative to steroids for Inflammatory Bowel Disease (IBD). Studies emphasize its 'smart targeting' capability: because PepT1 transporters proliferate on inflamed intestinal linings, KPV naturally accumulates exactly where it is needed most, sparing healthy tissue from suppression. 2024 dermatological reviews also point to its efficacy in psoriasis and eczema, where it dampens the 'itch-scratch' cycle by modulating skin immune responses. Furthermore, ophthalmic research has validated its ability to accelerate corneal healing without the risk of increased intraocular pressure often seen with corticosteroid eye drops.

Bibliography / Scientific References

Related Peptides

Research
BPC-157

Supports tissue repair and recovery in preclinical research

Research
TB-500 (Thymosin Beta-4 Fragment)

Promotes cell migration and new blood vessel growth

Peptide Information Guide
Administration Type
Injectable (Subcutaneous)

Injectable administration protocol for research.

Vial Strength
5mg10mg
Reconstitution
Reconstitute with 2ml bacteriostatic water
Dosage Options
0.5 mg (20 units)
Mon-Fri
Protocol for 5mg vial (Low Concentration)
0.5 mg (10 units)
Mon-Fri
Protocol for 10mg vial (High Concentration)
Schedule
5 days/week
Timing: One specific day.
Duration
According to the Doctor
Potential Side Effects
Injection site redness
lowcommon
Mild fatigue
lowrare
Research Use Only

This information is for research purposes only. Always consult with a healthcare professional before starting any peptide protocol. Individual responses may vary, and proper medical supervision is recommended for all peptide therapies.